Company intelligence / Profile preview

Haon Biosolutions

Ownership: Private
Development stage: Other

Overview

In large animal preclinical models of neonatal brain injury, HAON's lead candidate Can-Vas-001 has shown neuroprotective effects and significantly improved outcomes compared to standard care. These findings are considered translatable to other neurodegenerative diseases, opening up early partnering opportunities with pharma companies.

Therapeutic areas: Neurology
Modalities: Cell therapy
Industry: Biotech

Partnerships

No major partnerships publicly disclosed; early-stage partnering opportunities mentioned.

Beyond the preview

Go deeper on Haon Biosolutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Haon Biosolutions.

Explore the full profile